Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 6;13(2):175.
doi: 10.3390/cancers13020175.

Predicting Radiotherapy Impact on Late Bladder Toxicity in Prostate Cancer Patients: An Observational Study

Affiliations

Predicting Radiotherapy Impact on Late Bladder Toxicity in Prostate Cancer Patients: An Observational Study

Francesco Catucci et al. Cancers (Basel). .

Abstract

Background and purpose: The aim of our study was to elaborate a suitable model on bladder late toxicity in prostate cancer (PC) patients treated by radiotherapy with volumetric technique.

Materials and methods: PC patients treated between September 2010 and April 2017 were included in the analysis. An observational study was performed collecting late toxicity data of any grade, according to RTOG and CTCAE 4.03 scales, cumulative dose volumes histograms were exported for each patient. Vdose, the value of dose to a specific volume of organ at risk (OAR), impact was analyzed through the Mann-Whitney rank-sum test. Logistic regression was used as the final model. The model performance was estimated by taking 1000 samples with replacement from the original dataset and calculating the AUC average. In addition, the calibration plot (Hosmer-Lemeshow goodness-of-fit test) was used to evaluate the performance of internal validation. RStudio Software version 3.3.1 and an in house developed software package "Moddicom" were used.

Results: Data from 175 patients were collected. The median follow-up was 39 months (min-max 3.00-113.00). We performed Mann-Whitney rank-sum test with continuity correction in the subset of patients with late bladder toxicity grade ≥ 2: a statistically significant p-value with a Vdose of 51.43 Gy by applying a logistic regression model (coefficient 4.3, p value 0.025) for the prediction of the development of late G ≥ 2 GU toxicity was observed. The performance for the model's internal validation was evaluated, with an AUC equal to 0.626. Accuracy was estimated through the elaboration of a calibration plot.

Conclusions: Our preliminary results could help to optimize treatment planning procedures and customize treatments.

Keywords: decision supporting systems; predictive models; prostate cancer; toxicity prediction.

PubMed Disclaimer

Conflict of interest statement

No actual or potential conflict of interest exist regarding this article.

Figures

Figure 1
Figure 1
Summary of dose volume histograms (DVH) for nitourinary (GU) late toxicity with mean in blue and median in red and their relative inner confidence interval (IC).
Figure 2
Figure 2
The figure shows the value of Vdose (equal to 51.43 Gy) as a predictor of the development of late G ≥ 2 GU toxicity.
Figure 3
Figure 3
The figure shows a median of the Area under the ROC Curve (AUC) of the receiver operating characteristic curve (ROC) obtained for each dataset for internal validation.
Figure 4
Figure 4
Calibration plot of Hosmer–Lemeshow goodness-of-fit (GOF) test (p > 0.05).
Figure 5
Figure 5
(a) Bladder volume (%) of each patient related to V51: in blue patients who have developed a GU toxicity = 1, in red patients who have developed a GU toxicity ≥ 2. (b) Plot with S slope that trims patients according to the risk of developing a GU toxicity > 2 in relation to V51.
Figure 6
Figure 6
DVH-reduction model based on estimated complication probability (NTCP) under uniform irradiation (EUD) of the bladder.

Similar articles

Cited by

References

    1. Arnold M., Karim-Kos H.E., Coebergh J.W., Byrnes G., Antilla A., Ferlay J., Renehan A.G., Forman D., Soerjomataram I. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur. J. Cancer. 2015;51:1164–1187. doi: 10.1016/j.ejca.2013.09.002. - DOI - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2. [(accessed on 27 November 2017)];2020 Available online: https://www.nccn.org/professionals/physician_gls/default.aspx#site.
    1. Ouzzane A., Betrouni N., Valerio M., Rastinehad A., Colin P., Ploussard G. Focal therapy as primary treatment for localized prostate cancer: Definition, needs and future. Future Oncol. 2017;13:727–741. doi: 10.2217/fon-2016-0229. - DOI - PubMed

LinkOut - more resources